MDMA faces FDA panel in bid to become first-of-a-kind PTSD medication

United States News News

MDMA faces FDA panel in bid to become first-of-a-kind PTSD medication
United States Latest News,United States Headlines
  • 📰 mercnews
  • ⏱ Reading Time:
  • 72 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 32%
  • Publisher: 68%

By Matthew Perrone | Associated Press WASHINGTON — Federal health advisers are weighing the first-of-a-kind approval of MDMA, the mind-altering club drug, as a treatment for PTSD — part of a decade…

File photo: The Food and Drug Administration convened a panel of outside experts Tuesday to review the latest research on the drug, which appears to show it can help relieve post-traumatic stress disorder when combined with talk therapy.WASHINGTON — Federal health advisers are weighing the first-of-a-kind approval of MDMA, the mind-altering club drug, as a treatment for PTSD — part of a decadeslong effort by psychedelic advocates to win medical acceptance for the drug’s purported benefits.

The FDA panel will vote later Tuesday on whether to recommend the drug’s use for PTSD, which could set the stage for federal approval later this summer, though the FDA isn’t required to follow the group’s recommendations. Because MDMA causes intense psychological experiences, almost all patients in two key studies of the drug were able to guess whether they had received the MDMA or a dummy pill. That’s the opposite of the objectivity usually required for high-quality drug research, in which patients can’t tell whether they’ve received the drug being tested.

FDA regulators also have concerns about the drug’s safety risks, including whether patients may injure themselves if they are still impaired by the drug’s effects, which can last eight hours or more. MDMA is also associated with increased blood pressure. “It’s clear that MDMA-assisted therapy would be a welcome addition to the currently available options,” said Dr. Kelley O’Donnell, a New York University psychiatrist who helped conduct the MDMA studies. “I’ve seen firsthand how this treatment can be lifesaving for some.”Illegal ecstasy takes step toward becoming legal drug for PTSD

MDMA acts on two feel-good brain chemicals that are thought to improve talk therapy: serotonin and dopamine. Experts believe the drug helps patients confront past traumas by reducing fear and enhancing their connection and trust with therapists.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

mercnews /  🏆 88. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationPsychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationFederal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD. Advisers to the Food and Drug Administration are scheduled to vote on the drug's safety and effectiveness Tuesday afternoon. It potentially sets the stage for federal approval later this year.
Read more »

Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationPsychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationFederal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD.
Read more »

Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationPsychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationFederal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD.
Read more »

Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationPsychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationFederal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD
Read more »

Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationPsychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationFederal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD.
Read more »

FDA panel to evaluate psychedelic MDMA for treatment of PTSD for first timeFDA panel to evaluate psychedelic MDMA for treatment of PTSD for first timeThe U.S. Food and Drug Administration held a meeting to discuss a therapy based on the psychedelic drug MDMA for patients with post-traumatic stress disorder for the first time.
Read more »



Render Time: 2025-02-16 09:17:51